Corcept Therapeutics Announces Poster Presentations on Mifepristone for the Treatment of Patients With Cushing''s Syndrome at the 27th Annual American Association of Clinical Endocrinologists
(firmenpresse) - MENLO PARK, CA -- (Marketwired) -- 05/14/15 -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, oncologic and psychiatric disorders, today announced that four posters about mifepristone will be presented at the 24th annual American Association of Clinical Endocrinologists (AACE) being held at the Music City Convention Center in Nashville, TN from May 13 - 17, 2015.
"We are pleased that physicians have taken a strong interest in mifepristone and its potential to treat patients with Cushing''s syndrome," said Joseph K. Belanoff, M.D., Corcept''s Chief Executive Officer.
In addition to presentation of the four abstracts described below, AACE attendees will have the opportunity to attend a "Product Theatre" talk by Ty Carroll, M.D., whose topic will be "Not-So-Subclinical Cushing''s Syndrome." Corcept is a sponsor of Dr. Carroll''s presentation.
Korlym (mifepristone) 300 mg Tablets competitively blocks the glucocorticoid receptor (GR), one of the two receptors to which cortisol normally binds, thereby modulating the effects of excess cortisol in patients with Cushing''s syndrome. Since 2012, Corcept has made Korlym available as a once-daily oral treatment of hyperglycemia secondary to endogenous Cushing''s syndrome in adult patients with glucose intolerance or diabetes mellitus type 2 who have failed surgery or are not candidates for surgery. Korlym was the first FDA-approved treatment for that illness and the FDA has designated it as an Orphan Drug for that indication.
Endogenous Cushing''s syndrome is caused by prolonged exposure of the body''s tissues to high levels of the hormone cortisol and is generated by tumors that produce cortisol or ACTH. Cushing''s syndrome is an orphan indication that most commonly affects adults aged 20-50. An estimated 10-15 of every one million people are newly diagnosed with this syndrome each year, resulting in over 3,000 new patients annually in the United States. An estimated 20,000 patients in the United States have Cushing''s syndrome, half of whom are cured by surgery. Symptoms vary, but most people have one or more of the following manifestations: high blood sugar, diabetes, high blood pressure, upper body obesity, rounded face, increased fat around the neck, thinning arms and legs, severe fatigue and weak muscles. Irritability, anxiety, cognitive disturbances and depression are also common. Cushing''s syndrome can affect every organ system in the body and can be lethal if not treated effectively.
Corcept is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, oncologic and psychiatric disorders. Korlym, a first generation competitive GR antagonist, is the company''s first FDA-approved medication. The company is conducting a Phase 1/2 trial of mifepristone for the treatment of triple-negative breast cancer and is planning Phase 2 studies of CORT125134, one of its next-generation selective GR antagonists, for the treatment of Cushing''s syndrome and an oncology indication. The company has developed a proprietary portfolio of other selective GR antagonists that competitively block the effects of cortisol but not progesterone. It owns or has exclusively licensed extensive intellectual property covering the use of GR antagonists, including mifepristone, in the treatment of a wide variety of metabolic, oncologic and psychiatric disorders. It also holds composition of matter patents for its selective GR antagonists.
Charles Robb
Chief Financial Officer
Corcept Therapeutics
650-688-8783
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 14.05.2015 - 14:05 Uhr
Sprache: Deutsch
News-ID 1359046
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
MENLO PARK, CA
Phone:
Kategorie:
Drugs
Anmerkungen:
Diese Pressemitteilung wurde bisher 307 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Corcept Therapeutics Announces Poster Presentations on Mifepristone for the Treatment of Patients With Cushing''s Syndrome at the 27th Annual American Association of Clinical Endocrinologists
"
steht unter der journalistisch-redaktionellen Verantwortung von
Corcept Therapeutics (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
